The objective of this study was to define CYP2D enzymes in marmoset (Callithrix jacchus) liver microsomes, both at the activity level using debrisoquine as the model substrate, and at the protein level employing antibodies raised to human CYP2D6.
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Introduction
Non-human primates are employed regularly as non-rodent human surrogates during drug development. The most commonly used non-human primates are monkeys of the genus Macaca, including the cynomolgus monkey (Macaca fascicularis), rhesus monkey (Macaca mulatta) and Japanese macaque (Macaca fuscata). The macaque cytochromes P450, the most important enzyme system in drug metabolism, share high amino acid sequence identity with the human orthologue proteins (Uno et al., 2007) .
However, despite this similarity, these old world monkeys do not always generate metabolic data predictive of human metabolism (Guengerich, 1997; Bogaards et al., 2000) , they are relatively large in size and display other characteristics that can cause them to be challenging to use (Jacqz et al., 1988) . In contrast, the common marmoset (Callithrix jacchus), a new world monkey, is small and easier to handle, and is characterised by good fertility so that captive breeding is generally successful.
Furthermore, given the fact that the marmoset size is similar to that of rat, techniques and methodologies developed in rat can be readily adapted for use in marmosets (McAnulty, 1996; Smith et al., 2001) . Most studies on cytochrome P450 expression in primates have been carried out in the cynomolgus and rhesus monkeys (Uno et al., 2006 (Uno et al., , 2007 Iwasaki and Uno 2009; Uehara et al., 2010) . Only a limited number of investigations have been devoted to delineating the cytochrome P450 enzymes in marmoset liver, and these have been largely confined to immunological studies employing antibodies raised to rat and human cytochrome P450 enzymes (Schulz et al., 1996 (Schulz et al., , 1998 (Schulz et al., , 2001 Igarashi et al., 1997; Uno et al., 2010) .
One of the most important cytochrome P450 subfamilies involved in drug metabolism is CYP2D (Zanger, 2008) . The human CYP2D6 was the first drug This article has not been copyedited and formatted. The final version may differ from this version. DMD Fast Forward. Published on October 5, 2011 as DOI: 10.1124 at ASPET Journals on August 28, 2017 dmd.aspetjournals.org Downloaded from metabolising enzyme for which polymorphic expression was described, the antihypertensive debrisoquine being the drug employed in these studies, whose 4-hydroxylation is catalysed by this enzyme (Mahgoub et al., 1977) . At least two enzymes of the CYP2D subfamily, CYP2D17 and CYP2D44 have been identified in cynomolgus monkey (Iwasaki and Uno 2009; Uno et al., 2010) . These showed homologies in nucleotide and amino acid sequences of 94% and 93% between monkey CYP2D17 and human CYP2D6 and of 93% and 91% between monkey CYP2D44 and human CYP2D6, respectively. Moreover, both CYP2D17 and CYP2D44, similar to the human orthologue, could metabolise dextromethorphan and bufuralol (Iwasaki and Uno 2009; Uno et al., 2010) . Similarly the cDNA of two CYP2D enzymes, CYP2D19 and CYP2D30 from marmoset liver have been cloned and the proteins expressed in yeast cells (Hichiya et al., 2004) . These showed homologies in nucleotide and amino acid sequences of 92% and 91% between monkey CYP2D19 and human CYP2D6 and of 96% and 95% between monkey CYP2D30 and human CYP2D6, respectively. Both expressed enzymes demonstrated the capability to metabolise bufuralol and debrisoquine, albeit the regioselectivity of hydroxylation of debrisoquine was quite different between the two. Further, expressed CYP2D19 has been shown to hydroxylate propranolol (Narimatsu et al., 2011) . The objective of this study was to define CYP2D enzymes in marmoset liver microsomes, both at the activity and protein level, using debrisoquine as the model substrate and antibodies raised to human CYP2D6. This article has not been copyedited and formatted. The final version may differ from this version. 
Animals
Marmoset livers were taken from five male animals, ranging from 6 years 11 months to 8 years 8 months in age and 376 g to 571 g body weight (batch 1), and from 1 year 10 months to 11 years in age and 289 g to 397 g body weight (batch 2), housed at a 
Debrisoquine hydroxylation
The hydroxylation of debrisoquine was determined by a method based on that described by Kronbach et al. (1987) . For determination of the kinetics of debrisoquine hydroxylation, marmoset hepatic microsomal protein (0.75 mg; batch 1) was mixed with NADPH (6 mM) and Tris-HCl buffer (50 mM), pH 7.69 at 25°C in a total volume of 250 µl and pre-incubated for 3 minutes at 37°C. The reaction was initiated by the addition of [ and solvent B (acetonitrile), and the analyte was eluted using a linear gradient over 40 minutes; flow rate through the column was 0.5-1.0 ml/minute (HPLC method 1). The eluate was monitored for UV absorbance at 211 nm and for radioactivity using a β -RAM radioisotope system and data collected using Laura system software. Unreacted
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LC-MS/MS
For on-line LC-MS analysis the HPLC eluate from the column passed through a splitter, in the ratio of 9:1, with the majority of the eluate passing to waste (via UV and radio detectors) and the remainder to a Finnigan TSQ7000 mass spectrometer for positive ESI (ESI+). The spray voltage and the capillary temperature were set to 4.5 kV and 250°C, respectively. Nitrogen was used as sheath gas at a head pressure of 60 psi and also as auxiliary gas at 10 units. Mass spectrometric data were acquired over an appropriate mass range at a scan rate of 1 s/scan. The mass spectrum of metabolites was obtained by averaging several scans across the appropriate region of the mass chromatogram, with appropriate background subtraction. This mass spectrum was examined to identify a candidate protonated molecular ion, MH + for the compound, and any other structurally significant fragment ions resulting from in-source CID. The ESI+ mass spectrometric data were examined to identify candidate molecular ions for the metabolite(s) of interest, from which particular ions were selected for MS/MS analysis in the product ion scan mode. To achieve this, the Q1 mass analyser was set to pass only ions of mass corresponding to one of the candidate molecular ion species identified from the mass spectrum. This precursor ion was fragmented by CID in the Q2 region at a collision energy that was empirically optimised to provide maximum structural information (Argon, 2 mTorr). A mass spectrum of the fragments produced was recorded by scanning Q3 across a mass range from m/z 10 to a point several mass units above the selected precursor ion mass, employing a scan rate of 1 s/scan. Several This article has not been copyedited and formatted. The final version may differ from this version. scans were averaged to produce the product ion mass spectra of the putative metabolites.
NMR
For the analysis of hydroxylated metabolites of debrisoquine by NMR, larger scale incubations were performed. Initially, a 3-minute pre-incubation was carried out of the mixture comprising 50 mM Tris HCl buffer, pH 7.69 at 25°C, 6 mM NADPH, and 4 mg/ml pooled marmoset liver microsomal protein (batch 1) in a total volume of 35 ml. Reaction was initiated by the addition of 3.5 ml of 5 mM [ 
Western blotting
For the immunoblot analysis marmoset (batch 2), rat and human hepatic microsomal proteins were transferred electrophoretically to a Hybond-P polyvinylidene difluoride membrane. The amount of protein loaded was determined during preliminary that was demonstrated to be polymorphically expressed, which is the basis for the presence of poor and extensive metabolisers of the antihypertensive drug debrisoquine within the human population (Eiermann et al., 1998) . The purpose of the present study was to define the CYP2D subfamily in the liver of the marmoset, a potential surrogate primate animal species for human.
As the 4-hydroxylation of debrisoquine, the major metabolite in both rat and humans (Allen et al., 1975) , is used routinely to monitor CYP2D6 activity, the In order to define more precisely the hydroxylation positions, NMR analysis of metabolite fractions isolated using HPLC method 2 (Figure 1 ) from the large scale incubation was performed. The assignment of the NMR signals was made by longrange 2D COSY experiments (Table 1) . The results of this analysis show that, although debrisoquine was hydroxylated at the 4-position, this was not the principal metabolite but in fact a relatively minor metabolite (Table 2) positions, whereas these are only trace metabolites in rat and human urine (Allen et al., 1975 (Allen et al., , 1976 Idle et al., 1979) . In humans and rats 1-and 3-hydroxydebrisoquine that are subjected to ring-opening have also been reported (Eiermann et al., 1998) .
HPLC fractions 5, 7 and 8 were identified as possible open ring degradation products of debrisoquine in the present study, but these were not further identified by NMR analysis due to the lack of associated groups within their structure. Finally, a dihydroxy metabolite produced by marmoset liver microsomes, namely 6,7-dihydroxydebrisoquine, was also identified (Table 2) . A dihydroxy metabolite has been reported in a single human individual, characterised by the presence of 13 active CYP2D6 genes, but the position of the hydroxyl groups was not delineated (Eiermann et al., 1998) . The hydroxylated metabolites generated by marmoset liver microsomes are shown in Figure 5 .
Antibodies raised to CYP2D6 failed to immunoreact with rat liver microsomes, but single bands were evident when human (53.4 kDa) and marmoset (49.8 kDa) liver microsomes were probed (Figure 6 ), in agreement with a previous report (Uno et al., 2010) . A liver enzyme in marmoset monkey sharing high amino acid sequence similarity with human CYP2D6 has been reported by Igarashi et al.
(1997) and identified as CYP2D19. Interestingly, this CYP2D19 enzyme, unlike human CYP2D6, was found to have no debrisoquine 4-hydroxylase activity but high debrisoquine 5-, 6-, 7-, and 8-hydroxylase activities. Subsequently, Hichiya et al. In conclusion, we have demonstrated that marmoset liver microsomes are effective in hydroxylating debrisoquine at various positions and that they contain a protein that is immunorelated to human CYP2D6. The monohydroxylation of debrisoquine by marmoset liver is qualitatively similar but quantitatively different to human, with the major human metabolite (4-hydroxydebrisoquine) representing only about 2% of the total metabolites generated by marmoset liver microsomes.
Nonetheless the presence of CYP2D6-like metabolic activity in marmoset makes it a relevant surrogate species to use in drug development. Whether CYP2D is responsible for the hydroxylation of debrisoquine in the marmoset remains to be established.
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